Researchers studying mice have found evidence that an antibody common in the gut helps restrain cell division in the colon. In several mouse models, animals lacking the antibody developed more tumors than comparison mice. The team also investigated a receptor that may help explain the effect.
The study offers a new way to think about the relationship among the immune system, gut bacteria and the cells lining the intestine. It does not show that taking antibodies or a probiotic prevents colon cancer in people. The reported experiments are an early step toward understanding a mechanism.
The paper appeared in Nature on November 11, 2026. Rockefeller University’s account describes experiments involving immunoglobulin A, usually shortened to IgA, in mice and laboratory models.
Why would an antibody affect cell division?
Antibodies are often introduced as molecules that recognize germs. IgA is abundant at surfaces exposed to the outside world, including the gut, where it can interact with bacteria and other material. But the gut is also a living tissue that must continually renew its lining.
The cells lining the colon, called epithelial cells, have to divide to replace cells that are lost. Too little renewal can impair the tissue. Uncontrolled or abnormal division can contribute to the development of tumors. The challenge for the body is to maintain a balance rather than stop all cell division.
The Rockefeller team investigated whether IgA might participate in that balance. Their work suggests an interaction among antibodies, gut bacteria and a receptor on epithelial cells. This does not mean IgA is the only factor involved in colon cancer, which can develop through multiple biological pathways.
What happened in the mice?
The researchers compared mice that lacked IgA with mice that had it. The university reports that the animals were raised together, exposing them to the same food and germs. In the cancer models examined, the IgA-deficient mice developed more than twice as many colon tumors.
The team also gave IgA orally to deficient mice and reported that the increased tumor risk seen in those animals was no longer present in the experimental conditions. That observation supports further investigation of the mechanism. It does not establish an appropriate dose, formulation or outcome for human patients.
An animal model allows researchers to change one part of a biological system and observe effects in a living organism. Mice and people differ, however, and a model captures only selected aspects of a disease. The same result cannot be assumed in every mouse strain, cancer model or human population.
A possible brake on a normal process
The team examined the epithelial cells before tumors appeared and found changes in gene activity associated with cell proliferation. They focused on a receptor called DMBT1, which can bind IgA and had previously been associated with some cancers.
According to the researchers’ account, DMBT1 signaling in the presence of gut bacteria promoted epithelial-cell proliferation in their experiments. IgA binding acted as a brake on that process. In the proposed mechanism, removing IgA left the signal less restrained.
This is a model of how the components interact under the conditions studied. It should not be simplified into ‘bacteria cause cancer’ or ‘cell division is bad.’ Gut bacteria are diverse, epithelial renewal is necessary, and the balance among signals is what the researchers are trying to understand.
The work also shows why an antibody’s effect cannot always be understood by looking only at whether it binds a microbe. Interactions with the host’s own cells may matter too. Determining how broadly this mechanism applies will require additional experiments.
What does IgA deficiency mean?
Some people have very low or absent IgA, a condition known as IgA deficiency. The university says prior evidence has linked the condition with colorectal cancer risk. A link between a deficiency and a disease outcome does not mean that every person with the deficiency will develop cancer.
The new experiments provide a possible biological explanation worth testing, but a mechanism demonstrated in mice is not a complete account of risk in people. Human risk can depend on age, family history, other medical conditions and many environmental and biological factors.
Anyone who has been told they have IgA deficiency should discuss individual screening and health questions with their clinician. This study does not supply a personal risk estimate or a new clinical screening schedule.
Could people take IgA to prevent cancer?
The oral antibody experiment was performed in mice. Before a similar approach could be considered for people, researchers would need to determine whether it reaches the relevant part of the gut, how it behaves there, whether it is safe and whether it changes outcomes that matter clinically.
A treatment that alters a laboratory pathway is not automatically a treatment that prevents cancer. Human studies would need appropriate comparison groups and sufficient follow-up. They would also have to assess potential harms as well as benefits.
The researchers mention possible future strategies, including influencing the pathway or studying bacteria that might affect protective IgA responses. They describe such ideas as speculative. There is no basis in this study for recommending an unapproved antibody product or a particular probiotic as colon-cancer prevention.
What would researchers need to test next?
One question is whether the same receptor and antibody relationship operates in human colon tissue. Researchers could compare samples, test mechanisms in models using human cells and investigate whether findings are consistent across different biological conditions.
Another question is which components of the microbiome influence the process. A broad category such as ‘gut bacteria’ includes many species with different properties. Identifying a role for one organism or interaction would require evidence beyond the general observation that bacteria were present.
Independent replication is also valuable. Other teams can test the findings in different settings and examine alternative explanations. If the effect holds, subsequent work could explore whether modifying the pathway provides a benefit without interfering with normal tissue renewal or immune defense.
A broader lesson about prevention research
Cancer research often focuses on detecting or treating an existing tumor. This study examines an earlier stage: how normal tissue might keep cell division within healthy limits before tumors emerge. That is a scientifically interesting question even if no clinical intervention follows immediately.
The distinction between a mechanism and a treatment protects the value of the finding. Researchers have identified a potentially important interaction in mouse models. Whether it can improve prevention for people remains an open question, and established screening decisions should continue to be made with a qualified healthcare professional.
Explore the book: How to Do Hard Things: The Discomfort Trap
Be First to Comment